HUMAN LONGEVITY INC
United States of America (US)
Rating OpenCorporation: 9.46 su 100
Ranking 2018: 1719 su 602 aziende
Classificazione NACE primaria e secondaria:
• Research and experimental development on social sciences and humanities (7220)
• Other information technology and computer service activities (6209)
Descrizione dell'azienda
This company operates as a genomics and cell therapy-based diagnostic and therapeutic company. It was established in 2013 and conducts business from its registered head office located in San Diego, California.The company develops database on human genotypes and phenotypes to tackle the diseases associated with aging-related human biological decline; develops cell-based therapeutics to address age-related decline in endogenous stem cell function; focuses on cancer, diabetes and obesity, heart and liver diseases, and dementia; and engages in the sequencing and development of advanced diagnostics and therapeutics. It provides human genome sequencing; offers genomic analysis, personalized vaccines, and cell therapies, as well as supports predictive/preventive and personalized care, including cancer analysis, integrated health analysis, newborn screening and rare, and undiagnosed diseases; and Health Nucleus, a genomics-based health platform. The company offers database to pharmaceutical, biotechnology, and academic organizations.
Questionario OpenCorporation
La versione in sola lettura del questionario inviato a questa azienda è disponibile pubblicamente: vedi questionario.